2023

1. Multiple myeloma with t(11;14): impact of novel agents on outcome

   Blood Cancer Journal, Vol. 13, Núm. 1

2. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

   Cancers, Vol. 15, Núm. 5

3. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

   Haematologica, Vol. 108, Núm. 10, pp. 2753-2763